Basiliximab Induction

Basiliximab Induction is a pharmacotherapeutic strategy in liver transplant immunosuppression that belongs to the class of interleukin-2 receptor antagonist (IL-2RA) induction therapies, distinguished by its use of the monoclonal antibody basiliximab to selectively inhibit T-cell activation during the early post-transplant period.

217

Publications

9.1K

Citations

1.6K

Authors

487

Institutions

Publications per year

2017–2026

36

Authors

1.6K

  1. LF
    Lutz Fischer

    Universität Hamburg, Germany

    4 publications · 261 citations

    4

    h-index

  2. HH
    Hallvard Holdaas

    Oslo University Hospital, Norway

    4 publications · 216 citations

    4

    h-index

  3. MA
    Mohamed A. Bakr

    Mansoura University, Egypt

    4 publications · 60 citations

    4

    h-index

  4. KB
    Klemens Budde

    Charité - Universitätsmedizin Berlin, Germany

    4 publications · 283 citations

    4

    h-index

  5. AP
    Andreas Pascher

    Charité - Universitätsmedizin Berlin, Germany

    4 publications · 429 citations

    4

    h-index

1–5 of 1.6K

Venues

  1. Transplantation

    37 publications · 2.1K citations

    26

    h-index

  2. American Journal of Transplantation

    22 publications · 1.8K citations

    21

    h-index

  3. Transplantation Proceedings

    39 publications · 783 citations

    18

    h-index

  4. Clinical Transplantation

    15 publications · 352 citations

    12

    h-index

  5. The Journal of Heart and Lung Transplantation

    11 publications · 703 citations

    11

    h-index

1–5